Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines
August 14, 2025
[ad_1] Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases....
